PharmAthene, Inc. v. SIGA Technologies, Inc.
In a major pharmaceutical case, on remand Delaware Chancery finds plaintiff proved it had a reasonable expectation of profits at the time of breach; court accepts plaintiff expert’s damages model, but orders adjustments, particularly to sales quantity.
Courts Now Want Experts to Provide Critical Link in Criminal Securities Fraud
Comprehensive expert evidence, including statistical event study, required for government to prove causation in criminal securities fraud case.
United States v. Schiff
Comprehensive expert evidence, including statistical event study, required for government to prove causation in criminal securities fraud case.
Mass Drug Pricing Fraud Turns on Aggregate ‘Loss of Value’ Evidence
Massive claims of drug-overpricing turn on expert evidence of aggregate “loss of value” to Medicaid and other third-party payers.
In re Zyprexa Products Liability Litigation
Massive claims of drug-overpricing turn on expert evidence of aggregate “loss of value” to Medicaid and other third-party payors.
Proving Reasonable Royalty Damages Needs Credible Expert and Market Data
Court precludes a patent owner from testifying to lost profits damages, an area traditionally better served by experts and “true” market analysis.
Von der Ruhr v. Immtech International, Inc.
Court precludes a patent owner from testifying to lost profits damages, an area traditionally better served by experts and “true” market analysis.
Financial Expert Ensures Proof of Reasonable Royalty in Unjust Enrichment Case
1st Circuit upholds 3% reasonable royalty rate award for defendant’s misappropriation of plaintiff’s confidential biotech research.
Massachusetts Eye and Ear Infirmary v. QLT Phototherapeutics, Inc.
First Circuit upholds 3% reasonable royalty rate award for defendant’s misappropriation of plaintiff’s confidential biotech research.
Plaintiff Stakes $1.99 Million Lost Profits Award on Single ‘Benchmark’ Year
Plaintiff loses $1.99 million lost profits award by relying on flawed benchmark sales data.
Hinz v. Neuroscience, Inc.
Plaintiff loses $1.99 million lost profits award by relying on flawed benchmark sales data.
Abrons v Maree
The controlling stockholder of a company recently emerged from economic challenge seeks to buy out the remaining common stock through a tender offer and short-form merger. The stockholder seeks to preliminarily enjoin the closing of the tender offer ba ...
Dura Pharmaceuticals, Inc. v. Broudo
U.S. Supreme Court establishes the loss causation requirement in securities fraud litigation; i.e., it requires the plaintiffs to provide direct, causal link between alleged fraud and/or misrerpresentation by the corporate defendants and the inflated mark ...
Characterization stock options supported by evidence
The primary issues in this marital dissolution were how many shares of stock the husband held as a result of his exercise of stock options from his previous employer and whether the stock was marital or nonmarital property.
Moss v. Moss
Issues were how many shares of stock the husband held as a result of his exercise of stock options and whether the stock was marital or nonmarital.
Bristol-Myers Squibb v. Town of Wallingford
At issue is whether or not the property of Bristol-Myers Squibb Co. was overvalued.
Charriere v. Charriere
At issue is the valuation of wife's stock options.
Wife takes issue with award of stock dependent upon her continued employment
Wife appealed trial court's decision to award ex-husband stock options dependent on her continuing employment. The Court of Appeals upheld the trial court's finding that the stock options were communi ...
Wife says court erred in valuing husband's stock options
Wife contends that the trial court erred in calculating the value of husband's employee stock options in Eli Lilly & Co.
Knotts v. Knotts
At issue is the valuation of husband's stock in Eli Lilly and Company.
Daubert v. Merrell Dow Pharmaceuticals, Inc.
Landmark decision by the U.S. Supreme Court, which ended by promulgating a new “gatekeeping” function for federal judges and developing an evidentiary standard now known by a single name: Daubert.
Landmark Daubert Decision Develops New Standard for Admission of Expert Evidence
Landmark decision by the U.S. Supreme Court, which ended by promulgating a new “gatekeeping” function for federal judges and developing an evidentiary standard now known by a single name: Daubert.